Literature DB >> 33994741

Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis.

Pavan Kumar Jonnada1, Cherukuru Sushma2, Madhuri Karyampudi3, Anvesh Dharanikota1.   

Abstract

In the last two decades, India has witnessed a substantial increase in the incidence of breast cancer and associated mortality. Studies on the prevalence of molecular subtypes of breast cancer in India have reported inconsistent results. Therefore, we conducted a systematic review of observational studies to document the prevalence of molecular subtypes of breast cancer. A complete literature search for observational studies was conducted in MEDLINE and EMBASE databases using key MeSH terms ((molecular classification) OR (molecular subtypes)) AND (breast cancer)) OR (breast carcinoma)) AND (prevalence)) AND (India). Two reviewers independently reviewed the retrieved studies. The screened studies satisfying the eligibility were included. The quality of included studies was assessed using the selected STROBE criteria. The overall pooled prevalence of luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC) subtypes of breast cancer were 0.33 (95% CI 0.23-0.44), 0.17 (95% CI 0.12-0.23), 0.15 (95% CI 0.12-0.19), and 0.30 (95% CI 0.27-0.33), respectively. Subgroup analyses were performed by mean age of patients, time period, region, and sample size of the study. Among molecular subtypes of breast cancer, luminal A was the most prevalent subtype followed by TNBC, luminal B, and HER2-enriched subtypes. The overall prevalence of TNBC in India is high compared to other regions of the world. Additional research is warranted to identify the determinants of high TNBC in India. Differentiating TNBC from other molecular subtypes is important to guide therapeutic management of breast cancer. © Indian Association of Surgical Oncology 2020.

Entities:  

Keywords:  Breast cancer; HER2; Triple-negative breast cancers

Year:  2020        PMID: 33994741      PMCID: PMC8119535          DOI: 10.1007/s13193-020-01253-w

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  47 in total

1.  Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India.

Authors:  J Ghosh; S Gupta; S Desai; T Shet; S Radhakrishnan; P Suryavanshi; V Parmar; R Jalali; G Goyal; R Hawaldar; A Patil; N Nair; R A Badwe
Journal:  Indian J Cancer       Date:  2011 Oct-Dec       Impact factor: 1.224

2.  Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.

Authors:  Moses Ambroise; Mitra Ghosh; V S Mallikarjuna; Ann Kurian
Journal:  Asian Pac J Cancer Prev       Date:  2011

3.  Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.

Authors:  M G Nabi; A Ahangar; M A Wahid; S Kuchay
Journal:  Niger J Clin Pract       Date:  2015 May-Jun       Impact factor: 0.968

4.  Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.

Authors:  Sangeeta Verma; Amanjit Bal; Kusum Joshi; Sunil Arora; Gurpreet Singh
Journal:  APMIS       Date:  2012-07-26       Impact factor: 3.205

Review 5.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.

Authors:  Britta Weigelt; Frederick L Baehner; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

6.  Pattern of distant metastasis in molecular subtypes of carcinoma breast: An institutional study.

Authors:  S U Kunikullaya; J Poddar; A D Sharma; S Patel
Journal:  Indian J Cancer       Date:  2017 Jan-Mar       Impact factor: 1.224

7.  A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women.

Authors:  Anupama Mane; Khalid Ismail Khatib; Sanjay P Deshmukh; Shona M Nag; S P Sane; Bhushan P Zade
Journal:  J Clin Diagn Res       Date:  2015-09-01

8.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2007       Impact factor: 5.534

9.  Morphological profile and receptor status in breast carcinoma: an institutional study.

Authors:  Chandrika Rao; Jayaprakash Shetty; H L Kishan Prasad
Journal:  J Cancer Res Ther       Date:  2013 Jan-Mar       Impact factor: 1.805

10.  Predicting the molecular subtype of breast cancer based on mammography and ultrasound findings.

Authors:  S Rashmi; S Kamala; S Sudha Murthy; Swapna Kotha; Y Suhas Rao; K Veeraiah Chaudhary
Journal:  Indian J Radiol Imaging       Date:  2018 Jul-Sep
View more
  1 in total

1.  Molecular Profile and Clinico-pathological Characteristics of Breast Cancer in Central India: First Investigative Report.

Authors:  Aaryan Anand; Arpan Mishra; Harikrishna Damde; Arjun Saxena; Sanjay Kumar Yadav; Dhananjaya Sharma
Journal:  Indian J Surg Oncol       Date:  2022-01-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.